Nedim Turan
Research Subjects
Nedim Turan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hatice Odabas
Kartal Dr Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
2 shared publications - Nisanur Sariyar Busery
Kartal Dr Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
2 shared publications - Sedat Yildirim
Kartal Dr Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
2 shared publications - Cevher Burcu Salman
Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, 34865 İstanbul, Türkiye
1 shared publication - Cihad Tatar
Department of Colorectal Surgery Digestive Disease Institute, Cleveland Clinic Cleveland Ohio USA
1 shared publication - Deniz Isik
Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, 34865 İstanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2482
Clinicopathologic and Treatment-Related Determinants of Pathologic Complete Response and Survival Outcomes in Triple-Negative Breast Cancer: A Real-World Cohort Study
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy is an important prognostic indicator in triple-negative breast cancer (TNBC). Nevertheless, identifying clinicopathological characteristics associated with treatment response remains essential. This study aimed to evaluate factors associated with pCR and the relationship between pCR and survival outcomes in patients with TNBC receiving neoadjuvant therapy. Methods: In this retrospective cohort study, 153 patients with stage I–III TNBC who received neoadjuvant systemic therapy followed by surgery between April 2010 and January 2025 were evaluated. Clinicopathological characteristics, including age, menopausal status, body mass index (BMI), histological grade, HER2 status, Ki-67 proliferation index, tumor-infiltrating lymphocytes (TILs), clinical tumor stage, clinical nodal stage, and neoadjuvant treatment regimen were analyzed. Factors associated with pCR were evaluated using basic and expanded multivariable logistic regression models. The basic model included treatment regimen, histological grade, and clinical nodal status, while the expanded model additionally included HER2 immunohistochemical category, Ki-67, and clinical T stage. Complete-case analysis was performed to address missing data. Overall survival (OS) and event-free survival (EFS) were evaluated using the Kaplan–Meier method. Results: The basic multivariable logistic regression model included 143 patients and identified clinical node positivity as independently associated with lower odds of achieving pCR (adjusted OR = 0.285; 95% CI: 0.119–0.682; p = 0.005). Histological grade 3 (adjusted OR = 3.117; p = 0.010) and a pembrolizumab-containing treatment regimen (adjusted OR = 4.194; p = 0.015) were associated with higher odds of achieving pCR; however, the overall test for treatment regimen was not statistically significant (p = 0.112). In the expanded model (n = 133), clinical node positivity remained independently associated with lower odds of achieving pCR (adjusted OR = 0.318; 95% CI: 0.129–0.783; p = 0.013). Although the directions of the associations were maintained for histological grade 3 (p = 0.094) and the pembrolizumab-containing regimen (p = 0.052), neither association reached statistical significance. Tumor-infiltrating lymphocyte (TIL) data were available for only 67 patients, and no statistically significant association between TIL levels and pCR was observed in this subgroup. Patients who achieved pCR had more favorable overall survival (OS) and event-free survival (EFS) outcomes than those with residual disease. Conclusions: Baseline clinical nodal status was consistently associated with pathological complete response (pCR) across different multivariable models in patients with triple-negative breast cancer (TNBC). Findings regarding histological grade and pembrolizumab-containing neoadjuvant treatment regimens should be interpreted with caution, as these associations did not reach statistical significance in the expanded model. The high proportion of missing tumor-infiltrating lymphocyte (TIL) data further limits conclusions regarding this biomarker. Our study provides real-world evidence on neoadjuvant treatment response and survival outcomes and highlights the need for larger prospective cohorts to further investigate the relationships among clinical nodal status, histological grade, the tumor immune microenvironment, and response to immunotherapy.
- 29 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2482
Open AccessClinicopathologic and Treatment-Related Determinants of Pathologic Complete Response and Survival Outcomes in Triple-Negative Breast Cancer: A Real-World Cohort Study
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy is an important prognostic indicator in triple-negative breast cancer (TNBC). Nevertheless, identifying clinicopathological characteristics associated with treatment response remains essential. This study aimed to evaluate factors associated with pCR and the relationship between pCR and survival outcomes in patients with TNBC receiving neoadjuvant therapy. Methods: In this retrospective cohort study, 153 patients with stage I–III TNBC who received neoadjuvant systemic therapy followed by surgery between April 2010 and January 2025 were evaluated. Clinicopathological characteristics, including age, menopausal status, body mass index (BMI), histological grade, HER2 status, Ki-67 proliferation index, tumor-infiltrating lymphocytes (TILs), clinical tumor stage, clinical nodal stage, and neoadjuvant treatment regimen were analyzed. Factors associated with pCR were evaluated using basic and expanded multivariable logistic regression models. The basic model included treatment regimen, histological grade, and clinical nodal status, while the expanded model additionally included HER2 immunohistochemical category, Ki-67, and clinical T stage. Complete-case analysis was performed to address missing data. Overall survival (OS) and event-free survival (EFS) were evaluated using the Kaplan–Meier method. Results: The basic multivariable logistic regression model included 143 patients and identified clinical node positivity as independently associated with lower odds of achieving pCR (adjusted OR = 0.285; 95% CI: 0.119–0.682; p = 0.005). Histological grade 3 (adjusted OR = 3.117; p = 0.010) and a pembrolizumab-containing treatment regimen (adjusted OR = 4.194; p = 0.015) were associated with higher odds of achieving pCR; however, the overall test for treatment regimen was not statistically significant (p = 0.112). In the expanded model (n = 133), clinical node positivity remained independently associated with lower odds of achieving pCR (adjusted OR = 0.318; 95% CI: 0.129–0.783; p = 0.013). Although the directions of the associations were maintained for histological grade 3 (p = 0.094) and the pembrolizumab-containing regimen (p = 0.052), neither association reached statistical significance. Tumor-infiltrating lymphocyte (TIL) data were available for only 67 patients, and no statistically significant association between TIL levels and pCR was observed in this subgroup. Patients who achieved pCR had more favorable overall survival (OS) and event-free survival (EFS) outcomes than those with residual disease. Conclusions: Baseline clinical nodal status was consistently associated with pathological complete response (pCR) across different multivariable models in patients with triple-negative breast cancer (TNBC). Findings regarding histological grade and pembrolizumab-containing neoadjuvant treatment regimens should be interpreted with caution, as these associations did not reach statistical significance in the expanded model. The high proportion of missing tumor-infiltrating lymphocyte (TIL) data further limits conclusions regarding this biomarker. Our study provides real-world evidence on neoadjuvant treatment response and survival outcomes and highlights the need for larger prospective cohorts to further investigate the relationships among clinical nodal status, histological grade, the tumor immune microenvironment, and response to immunotherapy.
- Open Access
- 29 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 247
Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer
Background/Objectives: Tumor size is not included in the TNM staging system for colon cancer, and its prognostic significance remains controversial. We aimed to evaluate the impact of tumor size on recurrence-free survival (RFS) and overall survival (OS) in patients with stage T3N1 colon cancer. Methods: We retrospectively analyzed 336 patients with pathologically confirmed pT3N1 colon cancer who underwent curative resection between January 2015 and January 2025 at our tertiary institution. Clinicopathological features, adjuvant chemotherapy details, and survival outcomes were collected. Tumor size was measured pathologically, and a cutoff was determined by receiver operating characteristic (ROC) analysis. Kaplan–Meier and Cox regression analyses were performed to identify prognostic factors. Results: The optimal cutoff for tumor size predicting recurrence was 4 cm. Patients with tumors ≥ 4 cm had significantly lower 5-year RFS compared to those with smaller tumors (65.1% vs. 80.3%, p = 0.007). In multivariate analysis, tumor size ≥ 4 cm (HR: 2.014, 95% CI: 1.093–3.714, p = 0.025), ECOG performance status ≥ 2 (p = 0.005), positive resection margin (p = 0.011), and failure to complete adjuvant chemotherapy (p = 0.007) were identified as independent adverse prognostic factors for RFS. Tumor size was not independently associated with OS (p = 0.46). Adjuvant chemotherapy significantly improved both RFS (p < 0.001) and OS (p < 0.001). Conclusions: In patients with stage T3N1 colon cancer, tumor size ≥ 4 cm is an independent adverse prognostic factor for RFS. Incorporating tumor size into risk stratification, alongside TNM staging and treatment completion status, may improve prognostic assessment and guide clinical decision-making.
- 29 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 247
Open AccessPrognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer
Background/Objectives: Tumor size is not included in the TNM staging system for colon cancer, and its prognostic significance remains controversial. We aimed to evaluate the impact of tumor size on recurrence-free survival (RFS) and overall survival (OS) in patients with stage T3N1 colon cancer. Methods: We retrospectively analyzed 336 patients with pathologically confirmed pT3N1 colon cancer who underwent curative resection between January 2015 and January 2025 at our tertiary institution. Clinicopathological features, adjuvant chemotherapy details, and survival outcomes were collected. Tumor size was measured pathologically, and a cutoff was determined by receiver operating characteristic (ROC) analysis. Kaplan–Meier and Cox regression analyses were performed to identify prognostic factors. Results: The optimal cutoff for tumor size predicting recurrence was 4 cm. Patients with tumors ≥ 4 cm had significantly lower 5-year RFS compared to those with smaller tumors (65.1% vs. 80.3%, p = 0.007). In multivariate analysis, tumor size ≥ 4 cm (HR: 2.014, 95% CI: 1.093–3.714, p = 0.025), ECOG performance status ≥ 2 (p = 0.005), positive resection margin (p = 0.011), and failure to complete adjuvant chemotherapy (p = 0.007) were identified as independent adverse prognostic factors for RFS. Tumor size was not independently associated with OS (p = 0.46). Adjuvant chemotherapy significantly improved both RFS (p < 0.001) and OS (p < 0.001). Conclusions: In patients with stage T3N1 colon cancer, tumor size ≥ 4 cm is an independent adverse prognostic factor for RFS. Incorporating tumor size into risk stratification, alongside TNM staging and treatment completion status, may improve prognostic assessment and guide clinical decision-making.